100
Participants
Start Date
February 5, 2021
Primary Completion Date
November 5, 2026
Study Completion Date
November 5, 2026
Non-Interventional
No study treatment will be administered in this study
Acibadem City Clinic Multiprofile Hospital for Active Treatment, Sofia
Srinagarind Hospital - Ophthalmology, Khon Kaen
SBU Adana Sehir Training and Research Hospital, Adana
Specialized Hospital for Active Treatment of Eye Diseases - Varna, Varna
New York University School of Medicine - Oncology, New York
Icahn School of Medicine at Mount Sinai, New York
Chulalongkorn University, Bangkok
Phramongkutklao Hospital, Bangkok
Queen Sirikit National Institute Of Child Health - Pediatrics, Bangkok
Eskisehir Osmangazi University Medical Faculty Hospital, Eskişehir
West Virginia University, Morgantown
Soon Chun Hyang University Cheonan Hospital, Cheonan
University Hospitals Cleveland Medical Center, Cleveland
Chiang Mai University, Chiang Mai
Children's Hospital 1 - Ophthalmology Unit, Ho Chi Minh City
The Children's Hospital of San Antonio, San Antonio
Chung-Ho Memorial Hospital, Kaohsiung City
Prince of Songkla University - Ophthalmology, Hat Yai
Loma Linda University Eye Institute, Loma Linda
University of California San Francisco - Ophthalmology, San Francisco
V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children - ophtalmology, Moscow
St. Petersburg State Pediatric Medical University - ophtalmology, Saint Petersburg
Hue Central Hospital, Huế
Fundacion Oftalmologica de Santander Foscal, Floridablanca
SC Centrul Medical Unirea SRL, Iași
UCSD Shiley Eye Institute, Jacobs Retina Center, La Jolla
Lifespan - Women & Infants Hospital of RI, Providence
Clinica Universitaria Bolivariana, Medellín
Hacettepe University Medical Faculty, Ankara
Gazi University Medical Faculty Hospital, Ankara
Regeneron Pharmaceuticals
INDUSTRY